CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer

Speaking of SurgOnc

Content provided by Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

6M ago 15:33

MP3•Episode home

Rick Greene, MD, discusses with Susan Tsai, MD, MHS, the results of an analysis examining the efficacy of second-line gemcitabine/nab-paclitaxel (GnP) after first-line FOLFIRINOX in the neoadjuvant setting among patients with operable pancreatic cancer who were treated with a total neoadjuvant approach. Dr. Tsai is the senior author of, “CA19-9 Response to First-line Neoadjuvant FOLFIRINOX and Second-line Gemcitabine/nab- Paclitaxel in Patients with Operable Pancreatic Cancer.”

Dr. Tsai is Professor of Surgery and Chief of the Division of Surgical Oncology at The Ohio State University Comprehensive Cancer Center, Columbus, OH.

56 episodes

#Science #Annals of Surgical Oncology and Society of Surgical Oncology #Research #Globalcancersurgery #Surgicaloncology #Annals Of Surgical Oncology #Society Of Surgical Oncology #Podcasting Education